Skip to content

Advertisement

  • Oral presentation
  • Open Access

PReS-FINAL-2003: Remission and predictors of persistent disease activity at 30 years follow-up in a Norwegian cohort of juvenile idiopathic arthritis patients

  • 1,
  • 1,
  • 1 and
  • 1
Pediatric Rheumatology201311(Suppl 2):O6

https://doi.org/10.1186/1546-0096-11-S2-O6

Published: 5 December 2013

Keywords

  • Logistic Regression Analysis
  • Short Duration
  • Genetic Factor
  • Disease Duration
  • Juvenile Idiopathic Arthritis

Introduction

Long-term studies of remission rates in juvenile idiopathic arthritis (JIA) are few and difficult to compare because of different definitions of remission.

Objectives

To assess disease activity in a previously studied cohort of JIA patients after 30 years of disease duration and reveal predictors of persistently active disease.

Methods

A total of 259 patients with JIA, first referred to our hospital from 1980 to1985, were reexamined clinically after median 15 years of disease duration, and by mailed questionnaires after median 23 years. These patients were invited to attend the present study. All patients were assessed by questionnaires, and those with signs of active disease after 15, 23 and/or 30 years were invited to a clinical reexamination. Inactive disease and remission were defined according to the recently developed preliminary criteria for clinical remission in JIA. Logistic regression analyses were used to assess predictors of active disease.

Results

One hundred and seventy-one patients (67%) were included in the study. They were examined after a median of 30 (range 21-40) years of disease duration, median age was 39 (range 28-45) years and 74% were females. After 30 years, 59% of the patients were in clinical remission off medication, 7% were in remission on medication and 34% had persistently active disease compared with 57%, 10%, and 33%, respectively, after 15 years.

Table 1

Disease activity at 15 years follow-up

Not in remission at 30 years

Remission on med. at 30 years

Remission off med. at 30 years

Not in remission

57 (33%)

37

9

11

Remission on med.

17 (10%)

9

2

6

Remission off med.

97 (57%)

12

1

84

Total

171 (100%)

58 (34%)

12 (7%)

101 (59%)

med.: medication

Thirty-seven of 57 patients (65%) with active disease at 15 years follow-up had active disease at 30 years follow-up, and 20 patients (35%) went into remission on or off medication. Eighty-four of 97 patients (87%) in remission off medication remained in this category from 15 to 30 years follow-up. Patients in remission on medication at 15 years (n = 17) tended to flare or go into remission off medication. In total 121/171 patients (71%) had an unchanged category of disease activity from 15 to 30 years follow-up. Predictors of persistently active disease at 30 years follow-up were: being diagnosed with a JIA subgroup other than persistent oligoarticular and systemic JIA (OR 4.1, 95%CI 1.5-11.5, p = 0.006), being DR1 positive (OR 8.3, 95%CI 2.3-30.3, p = 0.001), a short duration of total time in remission (OR 9.0, 95% CI 3.0-26.7, p < 0.001), and not being in remission at 15 years follow-up (OR 13.7, 95%CI 4.9-38.4, p < 0.001), Nagelkerkes R2 = 65%.

Conclusion

The overall remission rates were stable between 15 and 30 years, even though one third of the patients changed category of disease activity. JIA subgroup, genetic factors and time without remission were important predictors of long-term outcome.

Disclosure of interest

None declared.

Declarations

Acknowledgements

Supported by the Norwegian Women's Public Health Association.

Authors’ Affiliations

(1)
Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway

Copyright

© Selvaag et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement